Head and Neck Cancers

Latest News

HPV Vaccinations Lowered HPV-Caused Cancers Rates in Patients Under the Age of 40
HPV Vaccinations Lowered HPV-Caused Cancers Rates in Patients Under the Age of 40

May 25th 2024

HPV vaccines in patients under the age of 40 may have lowered rates of HPV-related cancer compared with unvaccinated patients.

Trajectory of Symptom Severity Aids Follow-Up in Head and Neck Cancer Treatment
Trajectory of Symptom Severity Aids Follow-Up in Head and Neck Cancer Treatment

April 27th 2024

Atezolizumab After Definitive Local Therapy Fails to Improve Survival in HNSCC
Atezolizumab After Definitive Local Therapy Fails to Improve Survival in HNSCC

April 22nd 2024

FDA Approval of Oncology Drugs in March 2024
FDA Approval of Oncology Drugs in March 2024

April 1st 2024

Lenvatinib Plus Pembrolizumab Generates Responses But No OS Benefit in HNSCC
Lenvatinib Plus Pembrolizumab Generates Responses But No OS Benefit in HNSCC

March 6th 2024

Video Interviews
Podcasts
Latest CME Events & Activities

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

More News

© 2024 MJH Life Sciences

All rights reserved.